People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action.

[1]  T. Fleming,et al.  Innovations in Pediatric Therapeutics Development: Principles for the Use of Bridging Biomarkers in Pediatric Extrapolation , 2022, Therapeutic innovation & regulatory science.

[2]  P. Groop,et al.  Incidence rate patterns, cumulative incidence, and time trends for moderate and severe albuminuria in individuals diagnosed with type 1 diabetes aged 0-14 years: a population-based retrospective cohort study. , 2022, The lancet. Diabetes & endocrinology.

[3]  B. Duncan,et al.  IDF diabetes Atlas: Global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045 , 2021, Diabetes Research and Clinical Practice.

[4]  G. Filippatos,et al.  Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes. , 2020, The New England journal of medicine.

[5]  H. Heerspink,et al.  The Impact of Sotagliflozin on Renal Function, Albuminuria, Blood Pressure, and Hematocrit in Adults With Type 1 Diabetes , 2019, Diabetes Care.

[6]  A. Paterson,et al.  Risk Factors for Kidney Disease in Type 1 Diabetes , 2019, Diabetes Care.

[7]  A. Paterson,et al.  Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study. , 2016, Clinical journal of the American Society of Nephrology : CJASN.

[8]  D. Kohan,et al.  Endothelin and Endothelin Antagonists in Chronic Kidney Disease , 2014, Kidney international.

[9]  H. Parving,et al.  Aldosterone escape during blockade of the renin–angiotensin–aldosterone system in diabetic nephropathy is associated with enhanced decline in glomerular filtration rate , 2004, Diabetologia.

[10]  R. Bain,et al.  The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. , 1993, The New England journal of medicine.